IL-21 inhibitors(Interleukin-21 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors), Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Solid tumor

Inactive Indication-

Originator Organization

Must Bio Co., Ltd.

Active Organization

Must Bio Co., Ltd.

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

100 Clinical Results associated with MB-7

100 Translational Medicine associated with MB-7

100 Patents (Medical) associated with MB-7

Literatures (Medical) associated with MB-7

01 Jan 2010·Molekuliarnaia genetika, mikrobiologiia i virusologiia

[Complete genomic sequence of rapidly replicating strain MB-7 of hepatitis a virus and its characterization in comparison with nucleotide sequences of other hepatitis A virus strains].

Article

Author: Sviatchenko, V A ; Ternovoĭ, V A ; Chausov, E V ; Muntianova, M A ; Netesov, S V ; Kusliĭ, A G ; Bondarenko, T Iu ; Iashin, V V ; Kriuk, N I ; Nikulin, L G ; Nemtsov, Iu V ; Kiselev, N N

Complete nucleotide sequence of genomic RNA of hepatitis A virus (HAV) rapidly replicating strain MB-7 was determined. Comparison of nucleotide and deduced amino-acid sequences demonstrated the highest level of identity of MB-7 with strain HAS-15 (above 99%) and high homology with other HAV strains (HM 175/7, CR326, and GBM/HFS) used in production of anti-hepatitis A vaccines. MB-7 was classified as subgenotype IA. Phylogenetic analysis showed that MB-7 is most closely related to the strain HAS-15 and the HAV variants circulating in Russia. Comparative analysis of genomic differences between MB-7 and HAS-15 with other HAV strains revealed among changes characteristic of MB-7 those typical of the described earlier rapidly replicating HAV strains (nt. 149-162 in 5'-untranslated region and changes in the VP3 and 2C genes). These results suggest the functional importance of changes in above-mentioned regions of HAV genome for the increased replication level of MB-7 in vitro.

Voprosy virusologii

[The isolation and study of the characteristics of a cytopathic strain of the hepatitis A virus].

Article

Author: Karpovich, L G ; Mamaeva, N V ; Bondarenko, E P ; Konakova, V E ; Sosnovtsev, S V ; Nemtsov, Iu V ; Kalashnikova, T V ; Tiunnikov, G I ; Chizhikov, V E ; Maĭdaniuk, A G

A fast-growing cytopathic isolate of human hepatitis A virus (strain MB-7) was derived from fecal samples of infected patients and adapted to growth in FRhK-4 cell culture. A positive serum standard against HAV and electron microscopy were used to demonstrate that MB-7 belonged to human hepatitis A virus. The strain MB-7 induced plaque formation in FRhK-4 under agar overlay after 10-12 days of incubation. The PCR products of gene VP1 were cloned in E. coli and its primary structure was determined. MB-7 was shown to have more homology with HAV strains isolated in the USA and China.

100 Deals associated with MB-7

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Discovery	KR	Must Bio Co., Ltd.	17 Apr 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

MB-7

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation